Elisabetta Fenocchio

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Andrea Sartore‐Bianchi, Filippo Pietrantonio, Sara Lonardi et al. · Nature Medicine · 2022 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding, Jia Fan, Do‐Youn Oh et al. · The Lancet Oncology · 2023 · 247 citations · Full text

Medicine, Oncology, Pharmacology +10

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Andrea Sartore‐Bianchi, Sara Lonardi, Cosimo Martino et al. · ESMO Open · 2020 · 181 citations · Full text

Medicine, Oncology, Pharmacology +15

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Alessio Amatu, Luca Porcu et al. · The Oncologist · 2019 · 169 citations · Full text

Medicine, Molecular Medicine, Oncology +17